Phillip Chan, CEO of CytoSorbents, stated, "We are pleased to provide a brief update from our Stockholder Letter issued on January 31, 2023. If you have not already done so, we encourage you to review the letter, which highlights what we believe is our unique and compelling value proposition, and the proximity of major potential near-term catalysts, including the expected completion of the pivotal STAR-T RCT this year with the intent, with positive data, to submit for U.S. FDA and Health Canada marketing approval, and an expected return to Product Sales growth based on numerous growth initiatives."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CTSO:
- CytoSorbents Reports Fourth Quarter and Full Year 2022 Results
- CytoSorbents announces new European guidelines that consider hemoadsorption
- New European “Guidelines for the Management of Severe Perioperative Bleeding” Consider Hemoadsorption for the First-Time
- CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2022 Revenue
- CytoSorbents sees Q4 revenue $9.4M, consensus $8.9M
